it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.
.
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
https://grassfed.us/Dilibero-father-of-Releford-from-Guelph
. feedback to editors
.
.
.
.
.
.
feedback to editors
.
.
.